TY - JOUR
T1 - Clinical significance of c-reactive protein-to- albumin ratio with rectal cancer patient undergoing chemoradiotherapy followed by surgery
AU - Ide, Shozo
AU - Toiyama, Yuji
AU - Okugawa, Yoshinaga
AU - Oki, Satoshi
AU - Yasuda, Hiromi
AU - Fujikawa, Hiroyuki
AU - Yoshiyama, Shigeyuki
AU - Hiro, Junitiro
AU - Kobayashi, Minako
AU - Ohi, Masaki
AU - Araki, Toshimitsu
AU - Kusunoki, Masato
PY - 2017/10
Y1 - 2017/10
N2 - Background/Aim: This study was designed to evaluate the clinical significance of the C-reactive proteinto- albumin ratio (CAR) in patients with rectal cancer undergoing preoperative chemoradiotherapy (CRT) followed by surgery. Patients and Methods: This retrospective study evaluated the correlation between CAR and prognosis in 115 patients with locally advanced rectal cancer. We also carried out subgroup analyses limited to patients with low modified Glasgow prognosis score (mGPS) (score 0) or pathological TNM stage I-II [ypN(-)]. Results: CAR exhibited significant relationships with sex, tumor invasion, recurrence, serum carcinoembryonic antigen, and mGPS. Elevated CAR was an independent prognostic factor for overall survival (OS) and disease-free survival (DFS) among all patients. Elevated CAR also predicted poor OS and DFS in patients with pathological TNM stage I-II [ypN(-)] and low mGPS score. Conclusion: CAR is a promising predictor of survival and recurrence in patients with rectal cancer treated by CRT.
AB - Background/Aim: This study was designed to evaluate the clinical significance of the C-reactive proteinto- albumin ratio (CAR) in patients with rectal cancer undergoing preoperative chemoradiotherapy (CRT) followed by surgery. Patients and Methods: This retrospective study evaluated the correlation between CAR and prognosis in 115 patients with locally advanced rectal cancer. We also carried out subgroup analyses limited to patients with low modified Glasgow prognosis score (mGPS) (score 0) or pathological TNM stage I-II [ypN(-)]. Results: CAR exhibited significant relationships with sex, tumor invasion, recurrence, serum carcinoembryonic antigen, and mGPS. Elevated CAR was an independent prognostic factor for overall survival (OS) and disease-free survival (DFS) among all patients. Elevated CAR also predicted poor OS and DFS in patients with pathological TNM stage I-II [ypN(-)] and low mGPS score. Conclusion: CAR is a promising predictor of survival and recurrence in patients with rectal cancer treated by CRT.
UR - http://www.scopus.com/inward/record.url?scp=85031124484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031124484&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12022
DO - 10.21873/anticanres.12022
M3 - Article
C2 - 28982904
AN - SCOPUS:85031124484
SN - 0250-7005
VL - 37
SP - 5797
EP - 5804
JO - Anticancer research
JF - Anticancer research
IS - 10
ER -
